Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

30.86 -0.02 (-0.05%)

Streaming Delayed Price Updated: 3:01 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

What Analysts Are Saying About Genmab Stock ↗

April 09, 2025

Via Benzinga

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

March 31, 2025

From Genmab A/S

Via Business Wire

Does GENMAB A/S -SP ADR (NASDAQ:GMAB) match Peter Lynch’s “Invest in What You Know” philosophy? ↗

March 28, 2025

Peter Lynch was known for finding hidden gems in the market before they became mainstream. Is GENMAB A/S -SP ADR (NASDAQ:GMAB) one of those under-the-radar stocks that fits his legendary strategy?

Via Chartmill

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer ↗

March 27, 2025

Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.

Via Benzinga

Breaking Down Genmab: 4 Analysts Share Their Views ↗

March 11, 2025

Via Benzinga

NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗

January 03, 2025

Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout.

Via Chartmill

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. ↗

December 31, 2024

NASDAQ:GMAB is not too expensive for the growth it is showing.

Via Chartmill

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

March 27, 2025

From Genmab A/S

Via Business Wire

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

March 17, 2025

From Genmab

Via Business Wire

Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗

March 16, 2025

Large-cap stocks worst performers last week: TER, TTD, COIN, SAIL, GMAB, IBKR, DAL, ADBE, EXPE, HOOD, UAL, AAPL. Are they in your portfolio?

Via Benzinga

NASDAQ:GMAB stands out as a growth opportunity that won't break the bank. ↗

November 18, 2024

NASDAQ:GMAB, a growth stock which is not overvalued.

Via Chartmill

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

March 10, 2025

From Genmab A/S

Via Business Wire

Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—a stock with solid growth prospects and a reasonable valuation. ↗

March 10, 2025

GENMAB A/S -SP ADR was identified as an affordable growth stock. NASDAQ:GMAB is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.

Via Chartmill

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

March 04, 2025

Based on technical and fundamental analysis of NASDAQ:GMAB we find: GENMAB A/S -SP ADR (NASDAQ:GMAB) qualifies as a high growth stock and is consolidating.

Via Chartmill

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

February 20, 2025

From Genmab A/S

Via Business Wire

A Closer Look at 10 Analyst Recommendations For Genmab ↗

November 08, 2024

Via Benzinga

Preview: Genmab's Earnings ↗

November 05, 2024

Via Benzinga

In a market where value is scarce, NASDAQ:GMAB offers a refreshing opportunity with its solid fundamentals. ↗

February 19, 2025

Take a closer look at GENMAB A/S -SP ADR , a remarkable value stock. NASDAQ:GMAB excels in fundamentals and maintains a very reasonable valuation.

Via Chartmill

Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗

February 17, 2025

Uncover the potential of GENMAB A/S -SP ADR, a growth stock reasonably priced. NASDAQ:GMAB is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive...

Via Chartmill

NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗

January 28, 2025

Based on technical and fundamental analysis of NASDAQ:GMAB we find: GENMAB A/S -SP ADR (NASDAQ:GMAB) qualifies as a high growth stock and is consolidating.

Via Chartmill

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. ↗

January 21, 2025

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

January 10, 2025

For those who appreciate value investing, GENMAB A/S -SP ADR (NASDAQ:GMAB) is a compelling option with its solid fundamentals.

Via Chartmill

NASDAQ:GMAB appears to be flying under the radar despite its strong fundamentals. ↗

December 19, 2024

Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued.

Via Chartmill

Looking for growth without the hefty price tag? Consider NASDAQ:GMAB. ↗

December 10, 2024

While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.

Via Chartmill

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

December 09, 2024

From Genmab A/S

Via Business Wire

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

December 08, 2024

From Genmab A/S

Via Business Wire

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

December 07, 2024

From Genmab A/S

Via Business Wire

Why NASDAQ:GMAB Is a Standout High-Growth Stock in a Consolidation Phase. ↗

November 29, 2024

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

For those who appreciate value investing, NASDAQ:GMAB is a compelling option with its solid fundamentals. ↗

November 25, 2024

Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued.

Via Chartmill

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

November 05, 2024

From Genmab A/S

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Genmab A/S - American Depositary Shares (NQ:GMAB)

All News about Genmab A/S - American Depositary Shares

Starting at $3.75/week.

Subscribe Today